Show simple item record

dc.contributorUniversitat Ramon Llull. IQS
dc.contributor.authorGarcía-Fernández, Coral
dc.contributor.authorVirgilio, Tommaso
dc.contributor.authorLatino, Irene
dc.contributor.authorGuerra Rebollo, Marta
dc.contributor.authorF. Gonzalez, Santiago
dc.contributor.authorBorrós i Gómez, Salvador
dc.contributor.authorFornaguera Puigvert, Cristina
dc.date.accessioned2025-02-13T15:34:24Z
dc.date.available2025-02-13T15:34:24Z
dc.date.issued2024-08-22
dc.identifier.issn1873-4995ca
dc.identifier.urihttp://hdl.handle.net/20.500.14342/4908
dc.description.abstractmRNA-based vaccines symbolize a new paradigm shift in personalized medicine for the treatment of infectious and non-infectious diseases. However, the reactogenicity associated with the currently approved formulations limits their applicability in autoinflammatory disorders, such as tumour therapeutics. In this study, we present a delivery system showing controlled immunogenicity and minimal non-specific inflammation, allowing for selective delivery of mRNA to antigen presenting cells (APCs) within the medullary region of the lymph nodes. Our platform offers precise control over the trafficking of nanoparticles within the lymph nodes by optimizing stealth and targeting properties, as well as the subsequent opsonization process. By targeting specific cells, we observed a potent adaptive and humoral immune response, which holds promise for preventive and therapeutic anti-tumoral vaccines. Through spatial programming of nanoparticle distribution, we can promote robust immunization, thus improving and expanding the utilization of mRNA vaccines. This innovative approach signifies a remarkable step forward in the field of targeted nanomedicine.ca
dc.format.extent12 p.ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofJournal of Controlled Release. 2024;374:325-336ca
dc.rights© L'autor/aca
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.otherzwitterionicsca
dc.subject.othermRNAca
dc.subject.otherNanoparticlesca
dc.subject.otherDelivery systemsca
dc.subject.othercancerca
dc.subject.otherReactogenicityca
dc.titleStealth mRNA nanovaccines to control lymph node traffickingca
dc.typeinfo:eu-repo/semantics/articleca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc539ca
dc.identifier.doihttps://doi.org/10.1016/j.jconrel.2024.08.018ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/PN I+D/AC22/00042ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/MICIN i FEDER/Proyecto PID2021-125910OB-I00ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/SUR del DEC/SGR/2021 SGR 00537ca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint